Journal of Pharmacovigilance

Barry NJ Walters

Publications

• Research Article
  The Use of Angiotensin Converting Enzyme Inhibitors during the First Trimester of Pregnancy
  Author(s): Lyn Colvin, Barry NJ Walters, Andrew W Gill, Linda Slack-Smith, Fiona J Stanley, Lolkje TW De Jong-Van De Berg and Carol BowerLyn Colvin, Barry NJ Walters, Andrew W Gill, Linda Slack-Smith, Fiona J Stanley, Lolkje TW De Jong-Van De Berg and Carol Bower
  
  Background: The direct effects of angiotensin converting enzyme inhibitor (ACEI) medications on the fetus are difficult to determine since these medicines are usually administered to women presenting with high-risk pregnancies. The aim of this study was to provide an overview of the dispensing patterns, demographic characteristics and pregnancy outcomes of women dispensed an ACEI during pregnancy. Methods: Exposed pregnancies were all births in Western Australia, 2002-2005 where the mother was dispensed an ACEI under the Australian Pharmaceutical Benefits Scheme, compared with all other births during the same period. Result: From 2002 to 2005, there were 96,698 births in Western Australia. At least one form of ACEI was dispensed to 95 pregnant women (0.1%) and a further 677 pregnant women (0.7%) were dispensed an antihypertensive medication that was n.. View More»
  DOI: 10.4172/2329-6887.1000129

  Abstract PDF